Symptomatic Severe Bradycardia during Pazopanib Treatment

Pazopanib, a tyrosine kinase inhibitor targeting growth factor receptors, has diverse side effects including bradycardia. We present an extreme case of symptomatic bradycardia (28 bpm) in cardiac angiosarcoma patient on 800 mg/day pazopanib. Reducing to 600 mg/day restored heart rate to 53 bpm, underscoring potential severe bradycardia due to pazopanib, necessitating vigilant heart rate monitoring.